Search clinical trials for: severe renal impairment

Total 29240 results

Eli Lilly and Company

Recruiting

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Type 2 Diabetes

United States, Argentina, United Kingdom, Puerto Rico
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Renal Impairment
Guangdong Raynovent Biotech Co., Ltd

Recruiting

Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

Kidney Impairment

China
Novartis Pharmaceuticals

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spain, France
Centre Hospitalier Universitaire de Nīmes
CHU Arnaud de Villeneuve MONTPELLIER

Recruiting

Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients With Cardio Renal Syndrome With Severe Renal Impairment (CARDIOMEMS)

Heart Failure | Renal Insufficiency

France
Hellenic Society of Hematology
Sanofi

Not yet recruiting

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Renal Impairment

Greece
Zydus Therapeutics Inc.

Recruiting

A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects With Severe Renal Impairment and Normal Renal Function

Renal Impairment

United States
Amicus Therapeutics

Recruiting

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

Fabry Disease

Spain, United States, Japan, Australia, France, Portugal
Madrigal Pharmaceuticals, Inc.

Enrolling by invitation

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Renal Impairment

United States
Cerevel Therapeutics, LLC

Completed

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Renal Impairment

United States
Ascelia Pharma AB

Completed

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function (SPARKLE)

Severe Renal Impairment | Known or Suspected Focal Liver Lesions

United States, Italy, Germany, Poland, Russian Federation, Sweden, Turkey, Argentina, Colombia, Mexico
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Guangdong Raynovent Biotech Co., Ltd

Completed

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease

Kidney Impairment

China
Millennium Pharmaceuticals, Inc.

Completed

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

Renal Impairment | Healthy Volunteers

United States
Takeda

Completed

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

Type 2 Diabetes Mellitus

Japan
AstraZeneca
Quintiles, Inc.

Completed

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

Solid Tumours

France, Korea, Republic of, Spain
University of Texas Southwestern Medical Center

Completed

Neuromuscular Blockade in Patients With Severe Renal Impairment

Renal Impairment | Neuromuscular Blockade

United States
Portola Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

Germany
Idorsia Pharmaceuticals Ltd.

Completed

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Healthy | Renal Impairment

Portugal
Portola Pharmaceuticals
Novartis

Terminated

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Pfizer

Completed

Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment

Renal Insufficiency

United States
Astellas Pharma Global Development, Inc.

Completed

A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Renal Impaired | Gilteritinib | Normal Renal Function | Pharmacokinetics of ASP2215

United States, Bulgaria
University of Vermont
Medical University of South Carolina; University of Washington; University of...

Active, not recruiting

Communication During Hospitalization About Resuscitation Trial (CHART)

End Stage Renal Disease | Severe Life-limiting COPD | Severe Life-limiting Heart Failure | Severe Life-limiting Cirrhosis | Severe Life-limiting Malignancy | Severe Functional Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

Renal Impairment | Normal Renal Function

Germany
Centre Hospitalier Universitaire de Saint Etienne
Institut de Cancérologie de la Loire

Completed

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment (IRMYG)

Multiple Myeloma | Renal Failure

France, Belgium, Algeria, Lebanon
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Renal Impairment | Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

Renal Impairment

United States
Takeda

Completed

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"

Type 2 Diabetes Mellitus

Japan
Chiesi Farmaceutici S.p.A.

Completed

PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers

Chronic Obstructive Pulmonary Disease

Bulgaria
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Healthy Subjects | Severe Renal Impairment

Czechia
Amgen

Completed

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Hyperlipidemia | Mixed Dyslipidemia

United States
Celgene

Completed

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (POM Renal)

Multiple Myeloma | Renal Impairment

United States, Canada
Kowa Research Institute, Inc.

Completed

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Severe Hypertriglyceridemia

United States, Czechia, Belarus, Hungary, Russian Federation, Poland, Bulgaria, Georgia, Ukraine
Albert Einstein College of Medicine

Withdrawn

Safety and Efficacy of Apixaban in Severe Renal Impairment

Anticoagulant-induced Bleeding | Renal Disease, End Stage

United States
Amgen

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

Heart Failure

United States
Bristol-Myers Squibb

Completed

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Thrombosis

United States
Universitätsklinikum Hamburg-Eppendorf

Completed

Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment (GMMG-DANTE)

Multiple Myeloma

Germany, Greece
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers

Renal Impairment

Bulgaria
Mylan Inc.
Theravance Biopharma

Completed

Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment

Renal Impairment

United States
Acacia Pharma Ltd

Completed

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

Renal Disease, End Stage

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Human Immunodeficiency Virus (HIV) Infection

United States, Germany
Lexicon Pharmaceuticals
Sanofi

Completed

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control (SOTA-CKD4)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 4

United States, Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Novartis Pharmaceuticals

Completed

PK of Serelaxin in Severe Renal Impairment and ESRD (CRLX030A2102)

End-Stage Renal Disease | Renal Failure, Chronic

Germany
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Diabetes | Renal Impairment

Russian Federation
Novartis

Completed

Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.

Renal Insufficiency

Russian Federation
Novartis Pharmaceuticals

Completed

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Mild Moderate | or Severe Renal Impairment

Germany
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Hepatitis C Virus

United States, New Zealand
ViiV Healthcare

Completed

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Gilead Sciences

Completed

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

HCV Infection

United States, New Zealand, Germany

3

Subscribe